【24h】

Utilizing skin sparing technique in HN VMAT treatment planning

机译:利用皮肤备件技术在HN VMAT治疗计划中

获取原文
获取原文并翻译 | 示例
       

摘要

This study aims to demonstrate a specific treatment planning method and its effectiveness of sparing high dose to superficial skin for head and neck volumetric-modulated arc therapy (VMAT) treatments. A total of 10 patients with bilateral disease encompassing superficial neck nodes were planned as VMAT. Standard VMAT plans were created for each patient per written directive from physician, including target prescriptions, normal structure goals, and plan parameters. After these plans were created, low isodose levels were converted into dose structures, which are used to create a new skin sparing (SS) structure. With the new SS structure made, the original plan was copied to create a new SS plan. The new SS plan was re-optimized utilizing the newly created SS structure to help in decreasing dose to the superficial regions on the skin surface. The result of this treatment planning technique, comparing SS plans to original nonskin sparing (NSS) plans, provides a reduced dose of 10% to 15% to the skin surface in all cases. Although this technique reduces the dose to the skin, it can also reduce the dose to treatment volumes. Depending on physician intent, diagnosis, and disease, this method should only be used when the skin is not at risk, otherwise it could potentially cause underdosing to the disease site. All SS plans were considered clinically acceptable and provided adequate coverage to planning target volume (PTV), while reducing unwarranted high dose to superficial skin tissue. (C) 2018 American Association of Medical Dosimetrists. Published by Elsevier B.V. All rights reserved.
机译:本研究旨在证明一种特定的治疗计划方法及其对头部和颈部容量调制弧治疗(VMAT)处理的浅表皮肤的有效性。共有10名包含浅表颈部节点的双侧疾病患者作为VMAT。标准VMAT计划为每个书面指令从医生的每位患者创建,包括目标处方,正常结构目标和计划参数。在产生这些计划后,将低体状水平转化为剂量结构,用于产生新的皮肤备件(SS)结构。使用新的SS结构制作,已复制原始计划以创建新的SS计划。利用新创建的SS结构重新优化新的SS计划,以帮助将剂量减少到皮肤表面上的表面区域。将SS计划与原始Nonskin备件(NSS)计划的比较结果,在所有情况下,将SS计划与原始Nonskin备件(NSS)计划的结果进行比较,为皮肤表面提供10%至15%的剂量。虽然这种技术将剂量减少到皮肤上,但它也可以将剂量减少到治疗体积。根据医生意图,诊断和疾病,这种方法只应在皮肤没有风险时使用,否则可能导致疾病的疾病。所有SS计划被认为是临床上可接受的,并为规划目标体积(PTV)提供了足够的覆盖,同时减少了对浅色皮肤组织的无标记高剂量。 (c)2018年美国医疗剂量分子协会。 elsevier b.v出版。保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号